Individual differences in the effectiveness of intracoronary bone marrow cell transplantation assessed by gated sestamibi SPECT/FDG PET imaging
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
18513646
DOI
10.1016/j.nuclcard.2008.02.016
PII: S1071-3581(08)00053-6
Knihovny.cz E-zdroje
- MeSH
- dysfunkce levé srdeční komory diagnostické zobrazování prevence a kontrola MeSH
- fluorodeoxyglukosa F18 * MeSH
- hodnocení výsledků zdravotní péče metody MeSH
- infarkt myokardu diagnostické zobrazování chirurgie MeSH
- jednofotonová emisní výpočetní tomografie metody MeSH
- koronární cévy diagnostické zobrazování MeSH
- lidé středního věku MeSH
- lidé MeSH
- pozitronová emisní tomografie metody MeSH
- radiofarmaka MeSH
- transplantace kostní dřeně diagnostické zobrazování metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- fluorodeoxyglukosa F18 * MeSH
- radiofarmaka MeSH
BACKGROUND: The impact of different levels of tracer uptake on improvements of left-ventricular (LV) function was analyzed in patients treated by intracoronary bone marrow cell (BMC) transplantation. METHODS AND RESULTS: Thirty-one patients with irreversible damage after their first acute myocardial infarction (MI), as confirmed by sestamibi single-photon emission computed tomography (MIBI SPECT)/fluorodeoxyglucose positron emission tomography (FDG PET), underwent high-dose (1 x 10(8) cells) BMC transplantation, whereas 31 similar patients were randomly integrated into a control group. In 11 BMC-treated patients with very low sestamibi uptake at less than 30% of maximum in the infarcted area, the mean left-ventricular ejection fraction (LVEF) improved after 3 months of follow-up by 3% only, and mean end-diastolic/end-systolic volumes (EDV/ESV) enlarged by 10/1 mL (P = NS vs controls). In 20 BMC-treated patients with higher sestamibi uptake in the range of 31% to 50% of maximum, LVEF improved by 7%, and EDV/ESV decreased by 5/12 mL (P < .05 vs BMC-treated subgroup with low MIBI uptake and controls). No similar categorization was seen in the control group: in patients with higher sestamibi uptake or very low uptake, the LVEF increased by 2% and 3% only, and the EDV/ESV enlarged in both subgroups by 12/4 mL and 12/2 mL, respectively (P = NS). CONCLUSIONS: Our results suggest the capability of SPECT/PET imaging to select patients who will receive the maximum benefit from BMC therapy.
Zobrazit více v PubMed
J Am Coll Cardiol. 2001 May;37(6):1726-32 PubMed
J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67 PubMed
Circulation. 2003 Feb 25;107(7):1024-32 PubMed
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10440-5 PubMed
Circulation. 1997 Nov 4;96(9):2892-8 PubMed
Am Heart J. 2006 Nov;152(5):975.e9-15 PubMed
Circulation. 2002 Dec 10;106(24):3009-17 PubMed
J Am Coll Cardiol. 2002 Jan 2;39(1):30-6 PubMed
Lancet. 2003 Jan 4;361(9351):45-6 PubMed
Eur Heart J. 2006 Dec;27(23):2775-83 PubMed
J Nucl Cardiol. 2005 Jan-Feb;12(1):104-19 PubMed
Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):829-31 PubMed
Nature. 2001 Apr 5;410(6829):701-5 PubMed
Circulation. 1995 Feb 15;91(4):1006-15 PubMed
N Engl J Med. 2006 Sep 21;355(12):1210-21 PubMed
Circulation. 2002 Oct 8;106(15):1913-8 PubMed
Lancet. 2003 Jan 4;361(9351):47-9 PubMed
Circulation. 2004 Oct 26;110(17):2658-65 PubMed
Ann Nucl Med. 2003 May;17(3):169-79 PubMed
Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1146-51 PubMed
Association of polymorphisms of zinc metalloproteinases with clinical response to stem cell therapy
